
Human Pumilio proteins directly bind the CCR4-NOT deadenylase complex to regulate the transcriptome

ISIOMA I.I. ENWEREM,^{1,5} NATHAN D. ELROD,² CHUNG-TE CHANG,^{3,6} AI LIN,² PING JI,² JENNIFER A. BOHN,^{4,7} YEVGEN LEVDANSKY,^{3,8} ERIC J. WAGNER,² EUGENE VALKOV,^{3,8} and AARON C. GOLDSTROHM^{1,4}

¹Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455, USA

²Department of Biochemistry and Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, Texas 77550, USA

³Department of Biochemistry, Max Planck Institute for Developmental Biology, 72076 Tübingen, Germany

⁴Department of Biological Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA

ABSTRACT

Pumilio paralogs, PUM1 and PUM2, are sequence-specific RNA-binding proteins that are essential for vertebrate development and neurological functions. PUM1&2 negatively regulate gene expression by accelerating degradation of specific mRNAs. Here, we determined the repression mechanism and impact of human PUM1&2 on the transcriptome. We identified subunits of the CCR4-NOT (CNOT) deadenylase complex required for stable interaction with PUM1&2 and to elicit CNOT-dependent repression. Isoform-level RNA sequencing revealed broad coregulation of target mRNAs through the PUM-CNOT repression mechanism. Functional dissection of the domains of PUM1&2 identified a conserved amino-terminal region that confers the predominant repressive activity via direct interaction with CNOT. In addition, we show that the mRNA decapping enzyme, DCP2, has an important role in repression by PUM1&2 amino-terminal regions. Our results support a molecular model of repression by human PUM1&2 via direct recruitment of CNOT deadenylation machinery in a decapping-dependent mRNA decay pathway.

Keywords: Pumilio; CCR4-NOT; deadenylation; translational repression; mRNA decay

INTRODUCTION

RNA-binding proteins (RBPs) are crucial for regulating gene expression (Gerstberger et al. 2014; Gehring et al. 2017). Human PUM1 and PUM2 (PUM1&2) are members of the conserved Pumilio and Fem-3 binding factor (PUF) family of RBPs that typically repress gene expression (Wickens et al. 2002; Goldstrohm et al. 2018). PUM1&2 exhibit marked specificity for the consensus RNA sequence 5'-UGUANAUA, the Pumilio response element (PRE) (Zamore et al. 1997; Wang et al. 2002). They regulate PRE-containing mRNAs from diverse genes, predominantly acting as repressors that cause degradation of target

mRNAs and reduce protein production (Morris et al. 2008; Van Etten et al. 2012; Bohn et al. 2018; Goldstrohm et al. 2018; Wolfe et al. 2020; Yamada et al. 2020).

PUM1&2 have essential regulatory functions (Wickens et al. 2002; Arvola et al. 2017; Goldstrohm et al. 2018) and simultaneous inactivation of both is embryonically lethal in mice (Zhang et al. 2017; Lin et al. 2018; Uyhazi et al. 2020). PUM1&2 control growth, hematopoiesis, neurogenesis, behavior, fertility, and neurological functions (Goldstrohm et al. 2018; Lin et al. 2019; Uyhazi et al. 2020). They have been implicated in cancer (Kedde et al. 2010; Miles et al. 2012; Lee et al. 2016; Naudin et al. 2017; Bohn et al. 2018; Yamada et al. 2020), neurodegeneration, and epilepsy (Gennarino et al. 2015, 2018; Follwaczny et al. 2017). Recently, mutations in PUM1 were linked to the disorders PUM1-associated developmental

⁵**Present address:** Department of Biochemical Engineering, Emory University, Atlanta, GA 30322, USA

⁶**Present address:** Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei 11221, Taiwan

⁷**Present address:** Rockefeller University, Laboratory of Retrovirology, New York, NY 10065, USA

⁸**Present address:** Messenger RNA Regulation and Decay Section, RNA Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA

Corresponding author: agoldstr@umn.edu

Article is online at <http://www.najournal.org/cgi/doi/10.1261/rna.078436.120>.

© 2021 Enwerem et al. This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see <http://majournal.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

disability, ataxia, and seizure (PADDAS) and PUM1-related adult onset, cerebellar ataxia (PRCA) (Gennarino et al. 2015, 2018).

Given that all vertebrates have two *Pumilio* paralogs (Goldstrohm et al. 2018), do PUM1&2 have redundant, overlapping, or unique regulatory functions? In vitro RNA-binding studies showed that PUM1&2 display highly correlated specificities (Cheong and Tanaka Hall 2006; Lu and Tanaka Hall 2011; Van Etten et al. 2012; Jarmoskaite et al. 2019; Wolfe et al. 2020). RNA coimmunoprecipitation analysis demonstrated significant overlap of bound mRNAs but also provided evidence for unique subsets (Galgano et al. 2008; Morris et al. 2008; Hafner et al. 2010; Yamada et al. 2020). Phenotypic analysis of knockout mice lends support for both overlapping and unique functions (Goldstrohm et al. 2018; Lin et al. 2018, 2019; Uyhazi et al. 2020). While distinct expression patterns are likely relevant, both PUM1&2 are coincidentally expressed in a broad array of tissues and cell types (Goldstrohm et al. 2018; Spassov and Jurecic 2002). Systematic analysis of the individual and combined functional impact of human PUM1&2 on the transcriptome is necessary to address this important consideration.

Pumilio proteins from species ranging from insects to mammals share a primary structure that includes a large amino-terminal extension and a carboxy-terminal RNA-binding domain (RBD) (Goldstrohm et al. 2018). The RBD was structurally characterized and its RNA-binding affinity and specificity have been intensively studied (Wang et al. 2002; Lu et al. 2009). The RBD contributes to repression by antagonizing the Poly-Adenosine Binding Protein (PABP) and also by recruiting RNA decay factors (Kadyrova et al. 2007; Goldstrohm and Wickens 2008; Van Etten et al. 2012; Weidmann et al. 2014). However, in fruit flies, the RBD of *Pumilio* makes a minor contribution to repression (Weidmann and Goldstrohm 2012; Weidmann et al. 2014), which prompted us to examine the structure and function of human PUMs.

The amino-terminal regions of PUM1&2 are less conserved among orthologs and show no similarity to other proteins but do carry 70% identity between PUM1&2 paralogs (Weidmann and Goldstrohm 2012; Goldstrohm et al. 2018). In *Drosophila Pumilio*, three amino-terminal repression domains (RD1, 2, and 3) were identified (Weidmann and Goldstrohm 2012). In that same study, the amino-terminal regions of human PUM1&2 were shown to have repressive activity when artificially directed to an mRNA in *Drosophila* cells. However, the function of the PUM1&2 amino-terminal regions in translational repression and mRNA degradation remained untested in human cells.

The CCR4-NOT (CNOT) complex catalyzes the shortening of the 3' poly(A) tail of mRNAs in a process termed deadenylation and plays a pivotal role in initiating translational repression and mRNA decay (Goldstrohm and Wickens 2008). Importantly, the repressive activity of PUM1&2

was reduced when deadenylation was inhibited (Van Etten et al. 2012), suggesting a functional connection between PUMs and CNOT; however, the broader impact of this on the human transcriptome remained unknown.

The eight subunit human CNOT complex contains two distinct deadenylase enzymes, Pop2-type paralogs CNOT7 or CNOT8, and Ccr4-type paralogs, CNOT6 or CNOT6L (Goldstrohm and Wickens 2008). CNOT1 serves as a scaffold for additional CNOT subunits (i.e., CNOT2, 3, 9, 10, and 11) that mediate protein interactions with RBPs, microRNA-induced silencing complex, mRNA decay factors, and translational regulators (Fabian et al. 2013; Bhandari et al. 2014; Chen et al. 2014; Mathys et al. 2014; Sgromo et al. 2017; Raisch et al. 2018, 2019). Multiple CNOT components were reported to copurify with human PUMs, including all four deadenylases (Goldstrohm et al. 2006; Van Etten et al. 2012), but precise contacts were not mapped and functional roles of the CNOT components in PUM-mediated repression remained unknown.

In this study, we interrogate the role of the CNOT complex in repression by human PUM1&2 and find that several subunits are necessary for repressive activity. We then perform transcriptome-wide, isoform-level RNA sequencing and discover hundreds of target mRNAs that are coregulated by PUM1&2 and CNOT. We map the major repressive domains of PUM1&2, identify their direct interactions with the CNOT complex, and show that the mRNA decapping pathway plays an important role in the PUM-CNOT repression mechanism.

RESULTS

Compositional CNOT requirements for PUM-mediated repression

We and others have shown that human PUMs can accelerate degradation of PRE-containing mRNAs (Morris et al. 2008; Bohn et al. 2018; Goldstrohm et al. 2018; Wolfe et al. 2020) and implicated the CNOT deadenylase complex in this mechanism (Van Etten et al. 2012). However, the functional requirement for CNOT and the molecular basis of the PUM1&2-mediated repression remained unknown. To dissect the role of each CNOT subunit in PUM repression, we utilized PRE-containing Nano-luciferase (Nluc) reporter genes (Fig. 1A,B; Van Etten et al. 2012; Bohn et al. 2018). Cotransfected Firefly luciferase (Fluc) was used to normalize for variation in transfection efficiency. Repressive activity was measured by calculating the fold change of the Nluc 3xPRE reporter relative to a version wherein the 5'-UGU trinucleotide of the PRE that is essential for PUM-binding was substituted by 5'-ACA (Nluc 3xPRE mt) (Van Etten et al. 2012; Bohn et al. 2018). As expected, depletion of PUM1&2 (Fig. 1C) alleviated PRE-mediated repression in human HCT116 cells, whereas the nontargeting control (NTC) siRNAs had no effect (Fig. 1D).




FIGURE 1. Compositional CNOT requirements for PUM-mediated repression. Plotted data, listed in Supplemental Table S1, are graphed as mean log₂ fold change values \pm SEM. (A) Luciferase reporter constructs with Nluc followed by a 3'UTR containing three copies of WT or mutant (mt) Pumilio response element, PRE. Fluc served as control. (B) Architecture and module organization of the human CNOT deadenylase complex. (C) Western blot of PUM1&2 and CNOT1 confirming RNAi depletion in HCT116 cells. GAPDH served as loading control. (NTC) Nontargeting control siRNA. (D) Effect of depletion of PUM1&2 or CNOT1 on repression of the Nluc 3xPRE, relative to the Nluc 3xPRE mt reporter. NTC RNAi serves as a control. (*) *P*-value <0.05 relative to the PRE mt reporter (above x-axis) or between the indicated RNAi conditions (below the x-axis). *n* = 9. (E) Western blot of RNAi depletion of CNOT7 and PUM1&2. (F) RT-qPCR confirmed RNAi depletion of CNOT7&8 mRNAs, relative to NTC. (*) *P*-value of <0.05. *n* = 9. (G) Effect of RNAi depletion of CNOT7&8 and PUM1&2 on PRE-mediated repression. *n* = 9. (H) Western blot of RNAi depletion of CNOT6 and PUM1&2. (I) RT-qPCR measurement of RNAi-mediated depletion of CNOT6&6L mRNAs. *n* = 9. (J) Effect of RNAi-mediated depletion of CNOT6&6L and PUM1&2 on PRE-mediated repression.

We first depleted the central scaffold CNOT1 protein (Fig. 1C) and observed a complete loss of PRE–PUM repressive activity (Fig. 1D). Next, we systematically depleted the deadenylase enzymatic subunits. Efficient depletion was verified by Western blot for CNOT7 (Fig. 1E) as well as RT-qPCR for both CNOT7 and CNOT8 (Fig. 1F). Knockdown of CNOT7 and CNOT8 alleviated PRE-mediated repression (Fig. 1G). We found that depletion of both CNOT7 and CNOT8 was necessary, likely because both deadenylases associate with PUM1&2 (Van Etten et al. 2012) and were reported to be functionally redundant (Lau et al. 2009; Yi et al. 2018). Knockdown of the two Ccr4-type deadenylases, CNOT6 and CNOT6L (Fig. 1H,I), resulted in a modest but statistically significant reduction in repressive activity (Fig. 1J). Depletion of CNOT2 slightly reduced PRE–PUM repressive activity (Supplemental Fig. S1A,B). In contrast, depletion of CNOT3 (Supplemental Fig. S1A,B), CNOT9, CNOT10, or CNOT11 (Supplemental Fig. S1C–F) did not significantly impact repressive activity. These results reveal that the deadenylase enzyme subunits and central scaffold of the CNOT complex are necessary for PRE–PUM mediated repression in human cells.

The PUM-CNOT axis regulates a substantial proportion of the human transcriptome

We then set out to determine the impact of the PUM-CNOT repression mechanism on the transcriptome. First, we identified the mRNAs regulated by each PUM independently and in combination, revealing that they coregulate many RNAs. We utilized Poly(A)-ClickSeq (PAC-seq), an RNA sequencing approach that measures differential mRNA expression of 3'UTR isoform variants (Routh et al. 2017; Elrod et al. 2019), to analyze RNA isolated from cells depleted of PUM1, PUM2, or both. Efficient depletion of PUM1&2 was verified by western blot and was also observed in the PAC-seq data (Fig. 2A,B). To assess significant differences in gene expression, a 1.3-fold change cutoff in mRNA level (calculated for each RNAi condition relative to negative control RNAi condition, NTC) was used with an adjusted *P*-value <0.05 (Supplemental Table S2).

Simultaneous depletion of PUM1&2 altered the expression of 1590 genes, and we focused on the 890 genes that were up-regulated in a manner consistent with PUM-mediated repression (Fig. 2C). Depletion of either PUM1 or PUM2 individually, however, up-regulated 132 or 102 genes, respectively (Supplemental Fig. S2A–C). Comparison of the gene sets that are up-regulated by PUM1, PUM2, and PUM1&2 RNAi indicates that the majority of PUM-repressed genes are detected only when both are depleted (721 genes) (Supplemental Fig. S2D; Supplemental Table S3). Most of the remaining genes in the PUM1&2 gene set overlap with the individual PUM1 and/or PUM2 knockdowns (105 or 146, respectively), and

a small subset were exclusively up-regulated by either PUM1 (27 genes) or PUM2 (20 genes).

To identify direct targets of PUM1&2-mediated repression, we compared the up-regulated gene set (Supplemental Fig. S2E: “PUM1&2 RNAi”) with previously identified genes that contain PREs (Supplemental Fig. S2E: “PRE”) and that are bound by PUMs (Supplemental Fig. S2E: “Bound”) (Galgano et al. 2008; Morris et al. 2008; Hafner et al. 2010; Bohn et al. 2018). The majority of the PUM1&2 repressed genes have a consensus PRE (521 genes) and/or were found to be bound by PUMs (383 genes). When these three stringent criteria were collectively applied, we identified 335 direct PUM targets (Supplemental Fig. S2E; Supplemental Table S3).

Emerging evidence indicates that PUM1&2 can alternatively promote expression of certain genes (Naudin et al. 2017; Bohn et al. 2018; Wolfe et al. 2020), referred to as PUM-mediated activation (Goldstrohm et al. 2018). Here, we identified 62 genes that were down-regulated by depletion of PUM1&2, contain PREs, and are bound by PUMs (Supplemental Fig. S2F; Supplemental Table S3), providing additional support for direct PUM-mediated activation. This data will facilitate future efforts to elucidate the mechanism (Bohn et al. 2018; Goldstrohm et al. 2018).

Based on their crucial roles in PUM-mediated repression, we evaluated the effects of depletion of CNOT1 and CNOT7&8 on mRNA levels in the same PAC-Seq experiment. As anticipated for factors that have broad roles in mRNA decay, their depletion (Fig. 2A,B) up-regulated the levels of many genes including up-regulation of 3061 for depletion of CNOT1 and 2209 for depletion of CNOT7&8 (Fig. 2D,E). To identify PUM1&2 repressed target genes that are also repressed by CNOT, we compared the up-regulated gene sets from PUM1&2, CNOT1, and CNOT7&8 RNAi conditions. The PUM1&2 repressed genes overlap with 505 genes that are up-regulated by CNOT1 depletion and 423 genes by CNOT7&8 depletion (Fig. 2F). Further comparison revealed that 369 genes are up-regulated in all three RNAi conditions. Of those, 215 contain a consensus PRE, 161 are bound by PUMs, and 138 genes met all three criteria (Supplemental Fig. S2G; Supplemental Table S3). Together, these results identify many endogenous mRNAs that are repressed by PUM1&2 and the CNOT complex, providing new insight into the global impact of the PUM-CNOT repression mechanism.

The RNA-binding domains of PUM1&2 are necessary but not sufficient for repression

To understand how PUM1&2 cause CNOT-mediated repression, we dissected their repressive domains. First, we tested the contributions of their RBD and amino-terminal regions (Fig. 3A, RBD and N). We isolated this analysis to exogenously provided PUM1&2 by utilizing an altered




FIGURE 2. The PUM-CNOT axis regulates a substantial proportion of human transcriptome. (A) Western blot of RNAi depletion of PUM1, PUM2, or both simultaneously (PUM1&2), CNOT1, or CNOT7 and CNOT8 (CNOT7&8), from three biological replicates of HCT116 cells used for PAC-seq analysis. Cells treated with nontargeting control (NTC) siRNAs served as a negative control. GAPDH served as loading control. (B) RNAi depletion of PUM1, PUM2, CNOT1, CNOT7, and CNOT8 mRNAs measured in the PAC-seq data. Mean log₂ fold change values ±SEM (Supplemental Table S1) are plotted relative to NTC. (*) *P*-value <0.05 relative to the NTC control. *n* = 3. (C–E) Volcano plots of statistical significance (adjusted *P*-value) versus mean log₂ fold change of RNA levels, relative to NTC, measured by PAC-seq for each RNAi condition: (C) PUM1&2 RNAi; (D) CNOT1 RNAi; (E) CNOT7&8 RNAi. The number of genes that were up- or down-regulated by 1.3-fold or greater with an adjusted *P*-value <0.05 are reported in the inset box. PAC-seq data and statistics are reported in Supplemental Table S2. (F) Venn diagram of gene sets that were significantly up-regulated in each indicated RNAi condition. (*) *P*-value of <0.000001 (hypergeometric test for multiset overlap). Gene sets and statistics are reported in Supplemental Table S3.




FIGURE 3. The RNA-binding domains of PUM1&2 are necessary but not sufficient for repression. Mean log₂ fold change values ±SEM are plotted and listed in Supplemental Table S1. (*) *P*-value <0.05 relative to the negative control Halotag (HT) (above *x*-axis) or between the indicated proteins (below the *x*-axis). (A) Domain organization of PUM1 and PUM2 indicating the amino-terminal region (N) with putative repression domains (RD), Pumilio conserved motifs (PCMa and PCMb), and RNA-binding domain (RBD) with eight PUF repeats (R1-8), as previously designated (Weidmann and Goldstrohm 2012; Goldstrohm et al. 2018). Residue numbering on top. Putative cap binding residues, W466 and W350, are indicated below (Cao et al. 2010). The residues of the sixth PUF repeat that were changed in the altered specificity constructs, PUM1 R6as and PUM2 R6as, are shown below. The PUM1 residues linked to the diseases PADDAS, R1139W and R1147W, and PRCA, T1035S, are indicated below. (B) Altered specificity assay reporter gene, Nluc 3xPRE UGG, that specifically measures the activity of exogenous PUM1&2 (R6as) programmed to bind to the UGG motifs, relative to negative control Halotag (HT). *n* = 9. (C) Altered specificity reporter assay comparing the repressive activity of full length (FL) or RBD PUM1 or PUM2 R6as effectors, relative to negative control HT. *n* = 9. (D) Western blot of HT-tagged proteins from a representative experimental replicate from samples from C. GAPDH served as loading control. (E) Comparison of RBD to full length (FL) PUM1 (R6as) using the altered specificity reporter assay. Total mass of transfected DNA was balanced across transfections with an empty vector. *n* = 9. (F) Western blot of HT-tagged PUM1 proteins in E from a representative experimental replicate. Histone H3 served as loading control. (G) Same as E, except using PUM2 FL and RBD (R6as) proteins. *n* = 9. (H) Western blot of HT-tagged PUM2 proteins used in G from a representative experimental replicate.

specificity reporter gene assay. In this approach, each PUM is programmed to bind to a mutated form of the PRE that contains a 5'-UGG motif in place of the wild-type 5'-UGU (Fig. 3B, Nluc 3xPRE UGG), and therefore cannot be regu-

lated by the endogenous PUM1&2, as previously established (Van Etten et al. 2012; Weidmann and Goldstrohm 2012; Weidmann et al. 2014). To do so, the RNA recognition amino acids of the sixth PUF repeat of each protein

were changed to create PUM1 R6as (N1043S Q1047E) and PUM2 R6as (N921S Q925E) (Fig. 3A). This change confers new RNA sequence specificity for a guanine at the third nucleotide of the PRE, instead of uracil.

The repressive activity of the PUM1 R6as and PUM2 R6as proteins on the Nluc 3xPRE UGG reporter was measured relative to the negative control, Halotag protein (HT). Full length PUM1&2 R6as both had significantly greater repression activity than their corresponding RBDs (Fig. 3C). Notably, the RBD constructs were more abundantly expressed than the full length PUM1&2 R6as (Fig. 3D). In light of this observation, we compared the repressive activity and expression level across a titrated range of transfected RBD plasmid relative to full length PUM1 R6as (Fig. 3E,F) or PUM2 R6as (Fig. 3G,H). This titration allowed a more accurate assessment that, when expressed at near equal level to the corresponding full-length protein, each RBD was a much weaker repressor. This analysis confirms that, while the RBD is necessary, it is not sufficient for full PUM1&2 function, suggesting that the amino-terminal regions have important repressive activity.

Amino-terminal regions of human PUMs are potent repressors

We then focused on the potential activity of the PUM1&2 amino-terminal regions. Little information about these regions was available, with the exception of a small, conserved motif previously reported to be involved in translational repression by the *Xenopus* PUM2 ortholog (Cao et al. 2010). That motif was shown to bind the 7-methyl guanosine cap. We therefore tested the potential role of this motif by substituting the critical cap-binding tryptophan by glycine (Fig. 3A, PUM1 W466G, PUM2 W350G) and measuring the effect on PUM1&2 activity using the altered specificity reporter assay. Neither W466G nor W350G substitution in PUM1 and PUM2, respectively, alleviated repression (Supplemental Fig. S3). Thus, the cap-binding motif does not contribute to repressive activity.

To dissect the repressive activity of the amino-terminal regions of PUM1&2, independent of their RBDs, we used a tethered function reporter assay (Coller and Wickens 2007), wherein four binding sites for the MS2 phage coat protein are embedded in the 3'UTR of Nluc (Fig. 4A, Nluc 4xMS2) (Abshire et al. 2018). The MS2-HT negative control (a fusion of the MS2 coat protein to Halotag) did not significantly affect the Nluc 4xMS2 reporter relative to a control reporter that lacked MS2 binding sites, Nluc Δ MS2 (Fig. 4B). In contrast, the positive control, MS2-CNOT7 deadenylase, robustly repressed Nluc 4xMS2 but not Nluc Δ MS2 (Fig. 4B), showing that recruitment of CNOT7 is sufficient to repress expression. When the amino-terminal region of either PUM (MS2-PUM1 N and MS2-PUM2 N) was expressed (Fig. 4C), the Nluc 4xMS2 reporter protein was significantly reduced, dependent on

the MS2 binding sites (Fig. 4B). Using Northern blotting, we observed that repression by both MS2-PUM1 N and MS2-PUM2 N reduced Nluc 4xMS2 mRNA levels relative to the negative control (Fig. 4D,E). These data show that the amino-terminal regions of both PUM1&2 function to repress protein and mRNA expression.

The PUM1&2 amino-terminal regions function in repression via the CNOT deadenylase

Given that CNOT is necessary for PUM-mediated repression, we next asked if the amino-terminal regions of PUM1&2 require CNOT function. We first attempted RNAi knockdown but, interestingly, CNOT depletion concomitantly decreased the expression of the transfected PUM1&2 constructs (data not shown). As an alternative strategy to block CNOT-catalyzed mRNA decay that has been used successfully (Yamashita et al. 2005; Piao et al. 2010; Temme et al. 2010; Van Etten et al. 2012; Loh et al. 2013; Mishima and Tomari 2016), we coexpressed a combination of catalytically inactive CNOT7&8 dominant negative mutants (or HT negative control) and then measured the effect on repression by MS2-PUM1-N and MS2-PUM2-N (Fig. 4F). Importantly, the expression levels of PUM1&2 constructs were not altered (Fig. 4G). We observed that overexpression of CNOT7&8 mutants elicited a pronounced, significant decrease in repression by both MS2-PUM1 N and MS2-PUM2 N relative to control (Fig. 4F). In contrast, tethered MS2-CNOT7 was minimally perturbed by the CNOT7&8 mutants, which is an expected outcome where an active deadenylase is directly tethered to the reporter mRNA. These observations indicate that the amino-terminal regions of PUM1&2 require a functional CNOT complex to repress mRNAs.

Functional dissection of the amino-terminal repressive regions of PUM1&2

Having established that the amino-terminal regions of PUM1&2 have crucial repressive activity, we next mapped their repressive domains. Previously, we identified three repressive domains in *Drosophila* Pumilio (Weidmann and Goldstrohm 2012). Using sequence conservation as a guide, we delineated corresponding regions in human PUM1&2 (Fig. 3A, RD1–3) (Weidmann and Goldstrohm 2012; Goldstrohm et al. 2018). Notably, human PUM2 lacks a region corresponding to the *Drosophila* RD1.

We compared the ability of the individual RDs and RBDs of PUM1&2 to regulate the Nluc 4xMS2 reporter. We found that RD3 regions alone exhibited robust repression activity, matching that observed with the complete amino-terminal region (Fig. 5A), and exceeding that of the RBD. RD1 of PUM1 caused a moderate decrease in reporter expression whereas RD2 of PUM1 or PUM2 exhibited minimal effects. As PUM1 RD3 was expressed at a higher




FIGURE 4. Amino-terminal regions of human PUMs are potent repressors in isolation. Mean log₂ fold change values +/- SEM are plotted and listed in Supplemental Table S1. (*) *P*-value < 0.05 relative to the negative control MS2-HT (above x-axis) or between the indicated conditions (below x-axis). (A) Tethered function reporter gene, Nluc 4xMS2 pA, containing four MS2 coat protein stem–loop binding sites in its 3'UTR and terminating in a 3' poly(A) tail. (B) Repressive activity of the amino-terminal regions of PUM1&PUM2 (PUM1 N, PUM2 N) measured with the tethered function assay. PUM1&2 proteins were expressed as fusions to the RNA-binding domain of MS2 phage coat protein with a V5 epitope tag. MS2 fused to Halotag (HT) or CNOT7 served as negative and positive controls, respectively. Nluc ΔMS2 pA reporter, which lacked the MS2 binding sites, served as a negative control reporter gene. The *left* graph shows the activity of each effector relative to MS2-HT for each reporter, Nluc ΔMS2 pA or Nluc 4xMS2 pA. The *right* graph shows the activity of each effector on the Nluc 4xMS2 pA relative to the Nluc ΔMS2 pA. *n* = 9. (C) Western blot of proteins from a representative experimental replicate from samples in B. Histone H3 served as a loading control. (D) Northern blot of Nluc 4xMS2 pA mRNA measured the effect of tethered MS2 fusions of PUM1 N, PUM2 N, or HT. Ethidium bromide (EtBr) and northern blot detection of rRNA assessed RNA integrity and loading. *n* = 3. (E) Quantitation of the northern blot in D. (F) The role of CNOT in repression by tethered MS2 fusions of PUM1 N and PUM2 N was assessed using the Nluc 4xMS2 pA reporter. CNOT activity was inhibited by overexpressing HT fusions of dominant negative mutant CNOT7&8 proteins (CNOT7&8 mt, +), compared to HT (-). Repression relative to MS2-HT negative control. *n* = 9. (G) Western blot of V5-tagged proteins and HT-tagged CNOT7&8 mt from a representative experimental replicate from samples in F.




FIGURE 5. Functional dissection of the amino-terminal repressive regions of human PUM1&2. Mean log₂ fold change values ±SEM are plotted and listed in Supplemental Table S1. (*) *P*-value <0.05 relative to the negative control MS2-HT (above x-axis). (A) Activity of putative repression domains (RD1, RD2, and RD3) and RBDs of PUM1&2, fused to MS2 coat protein and HT, measured in tethered function assays. MS2 fusions of HT and CNOT7 served as negative control and positive control, respectively. *n* = 9. (B) Western blot of MS2-tagged proteins from a representative experimental replicate from samples in A. GAPDH served as loading control. (C) Activity of MS2-PUM1 RD3 compared to PUM1 N, PUM1 RD1 and PUM1 RD2 MS2 fusions relative to MS2-HT. Transfected plasmid mass is indicated and is balanced across conditions with an empty vector. *n* = 9. (D) Western blot of V5-epitope tagged proteins from a representative experimental replicate from samples in C. Histone H3 service as a loading control. (E) Effect of PUM1 N, PUM1 RD3, PUM2 N and PUM2 RD3 MS2 fusion effectors on Nluc 4xMS2 mRNA levels, relative to MS2-HT, measured by RT-qPCR. *n* = 9. (F) Western blot of V5-tagged proteins from a representative experimental replicate from samples in panel E.

level than the other fragments (Fig. 5B), we then titrated the PUM1 RD3 plasmid while keeping the total mass of transfected plasmid DNA constant across conditions. By this approach, we found that tethered PUM1 RD3 repression activity (Fig. 5C) and expression level (Fig. 5D) increased proportionally with the mass of transfected plasmid, plateauing at more than eightfold observed level of repression. By western blot, the level of PUM1 RD3 protein at 20 ng of transfected plasmid was comparable to that of PUM1 N, RD1, or RD2 at 85 ng (Fig. 5D). We also measured the effect of the amino-terminal regions and RD3 of PUM1&2 on levels of the Nluc 4xMS2 reporter

mRNA by performing RT-qPCR. All four constructs significantly reduced the reporter mRNA level relative to the negative control MS2-HT (Fig. 5E,F). Based on these results, we conclude that RD3 of PUM1&2 confers the major repressive activity and can function autonomously to reduce protein and mRNA levels.

Repression domain 3 of PUM1&2 binds directly to the CNOT complex

We next asked if RD3 of each PUM interacts with CNOT in cells. To test this, V5 epitope-tagged PUM1 RD3 or PUM2

RD3 “bait” proteins, or V5-tagged CNOT8 positive control, were expressed in HCT116 cells and immunopurified. To disrupt potential RNA-mediated interactions, RNA in each sample was degraded by addition of RNases, as verified by gel electrophoresis (Supplemental Fig. S4). Following extensive washing, the bound proteins were eluted and probed in western blots to detect CNOT subunits. As a negative control, immunoprecipitations were performed from cells transfected with an empty expression vector (Fig. 6A, control). We observed that multiple CNOT subunits (CNOT1, 2, 3, 6, and 7) coimmunoprecipitated with PUM1 RD3 and PUM2 RD3 and the positive control bait, but not the negative control (Fig. 6A). Thus, RD3 of PUM1&2 associates with the CNOT complex.

We then confirmed the PUM-CNOT interaction using an independent approach and further investigated the protein–protein contacts. First, we reconstituted a recombinant CNOT complex containing all eight core subunits (Raisch et al. 2019). We then performed in vitro “pull-down” assays using recombinant bead-bound PUM1&2 domains (RD1, RD2, RD3, and RBD) that had carboxy-terminal maltose binding protein (MBP) and amino-terminal StrepII (Strep) affinity tags (Fig. 6B). Following incubation and washing, the bound complexes were eluted and analyzed by Coomassie-stained SDS-PAGE. We observed that the CNOT complex interacted with RD3 of PUM1&2, with all CNOT subunits detected (Fig. 6B), whereas RD1 and RD2 did not appreciably interact. We also note that CNOT subunits were present in the pull-downs of PUM1&2 RBDs, albeit at a lower level.

To delineate the component(s) of the CNOT complex that directly interacts with RD3, we tested the ability of PUM1&2 RD3 regions to bind individual recombinant, purified modules of the CNOT complex using the in vitro pull-down assay. This revealed that the NOT module (Boland et al. 2013), consisting of the carboxy-terminal CNOT1 fragment, and structured regions of CNOT2 and CNOT3, was directly bound by RD3 of both PUMs but




FIGURE 6. Repression domain 3 of PUM1&2 binds directly to the CNOT complex. (A) Coimmunoprecipitation of RD3 domains of PUM1&2 proteins from HCT116 cells. V5-CNOT8 served as a positive control and empty vector served as a negative control. Western blot of each V5-tagged bait protein in cell extracts (Input) and anti-V5 immunoprecipitates (IP). Endogenous CNOT subunits were detected by western blot. Cell extracts were treated with RNases A and 1, and RNA digestion was confirmed in Supplemental Figure S4. (B) Coomassie stained SDS-PAGE of in vitro pull-down assays with recombinant purified RD1, RD2, RD3, and RBD domains of PUM1 and PUM2, produced as fusions with maltose binding protein (MBP) and StrepII (strep) affinity tags with the intact purified CNOT complex (Input). MBP-strep served as negative control. (C) Same as B, but with the four indicated CNOT modules (Input). Diagram of CNOT modules is shown in Figure 1B.

not the MBP-Strep negative control (Fig. 6C). In contrast, no interaction was detected with the NOT10/11, catalytic (CNOT6/7), or CNOT9 modules. This analysis precisely delineates the contacts between RD3 and the NOT module, providing a key insight into the molecular mechanism by which PUM1&2 promotes CNOT-mediated repression.

The 3' poly(A) tail and 3' end accessibility are important for repression by PUM1&2 amino-terminal regions

Previously we observed that the poly(A) tail was necessary for efficient repression by full length PUM1&2 (Van Etten et al. 2012). Here, we compared the ability of the amino-terminal regions of PUM1&2 to repress the Nluc 4xMS2 reporter with a poly(A) tail (Fig. 4A) to a similar reporter that terminates with a MALAT1 triple-helical RNA structure (Fig. 7A; Abshire et al. 2018). If deadenylation is essential

for PUM-repression, then the poly(A) tail should be required. In contrast, the MALAT1 3' end is processed to yield a triple helix structure that stabilizes an mRNA from 3' decay while supporting translation (Wilusz et al. 2012; Brown et al. 2014; Wilusz 2016). Thus, if PUM1&2 retain the ability to repress the MALAT1 reporter, this would indicate an additional deadenylation-independent repression mechanism.

When tethered, the amino-terminal regions of PUM1&2 exhibited significantly reduced repressive activity on the MALAT1 reporter relative to the polyadenylated reporter




FIGURE 7. PUM1&2-mediated repression is directed via the decapping-dependent pathway. Mean log₂ fold change values \pm SEM are plotted and listed in Supplemental Table S1. (*) *P*-value <0.05 relative to the negative control MS2-HT (above x-axis) or between the indicated conditions (below the x-axis). (A) The Nluc 4xMS2 MALAT1 reporter gene used in the tethered function assays. The 3' end of this reporter terminates with the MALAT1 triple helix structure. (B) Repressive activity of MS2-fused PUM1 N, PUM2 N, or CNOT7 effector proteins measured by the tethered function assay with either Nluc 4xMS2 pA (black bars) or MALAT1 (blue) reporters, relative to MS2-HT negative control. *n* = 9. (C) Western blot of MS2-tagged protein from a representative experimental replicate for B. GAPDH served as a loading control. (D) The tethered function assay was used to determine the effect of overexpressed, dominant negative DCP2 mutant (DCP2 mt) on repression activity of MS2-tethered PUM1 N, PUM2 N, or CNOT7 effector proteins, relative to MS2-HT negative control. Repression of Nluc 4xMS2 pA and Nluc 4xMS2 MALAT1 reporters was measured without (-) or with (+) overexpressed DCP2 mt. *n* = 9. (E) Western blot of V5-tagged proteins and myc-tagged DCP2 mt from a representative experimental replicate for D.

(Fig. 7B,C), indicating that the poly(A) tail and/or the accessibility of the 3' end are important. Consistently, repression by tethered CNOT7 was also reduced on MALAT1 versus poly(A). These results for PUM1&2 amino-termini and CNOT7 effector proteins are consistent with the involvement of deadenylation of the 3' end of the mRNA in their repressive mechanisms. The observed residual inhibitory activity on the MALAT1 reporter may be due to the ability of the CNOT complex to cause translational repression and 5' decapping (see Discussion) (Behm-Ansmant et al. 2006; Cooke et al. 2010; Waghray et al. 2015). Indeed, Northern blotting indicates that the amino-terminal regions of PUM1&2 reduce the mRNA level of the Nluc 4xMS2 MALAT1 mRNA (Supplemental Fig. S5).

PUM1&2-mediated repression is directed via the decapping-dependent pathway

Following poly(A) tail shortening by the CNOT complex, the mRNA may be degraded by either the 5'-to-3' decapping-dependent decay pathway or the 3'-to-5' decay pathway (Garneau et al. 2007). To investigate if decapping is necessary for PUM-mediated repression, we inhibited decapping by overexpressing a dominant negative DCP2 mutant in cells (Covarrubias et al. 2011; Chang et al. 2014; Erickson et al. 2015; Sgromo et al. 2017). We then tested the ability of tethered PUM1 or PUM2 amino termini to repress the pA and MALAT1 reporters in this mutant background, compared to control. We observed that overexpression of the DCP2 mutant significantly reduced repression by each effector on both reporters (Fig. 7D,E). These results indicate that PUM1&2-mediated repression is directed via the decapping-dependent pathway, even in the absence of the poly(A) tail and deadenylation.

DISCUSSION

Pumilio proteins have emerged as archetypal sequence-specific RNA-binding factors (Wickens et al. 2002; Arvola et al. 2017; Goldstrohm et al. 2018). Here, we reveal new insights into PUM1&2-mediated regulation with individual mRNAs and on the global transcriptome. We mapped the domains of PUM1&2 that elicit repression, determined the complement of the requisite corepressors, identified new domains of PUM1&2 that directly bind to the CNOT deadenylase complex, and measured the impact of the PUM-CNOT repression mechanism on the transcriptome.

Model of PUM1&2-mediated repression

We found that the amino-terminal region of PUM1&2, in particular the RD3 region, is principally responsible for PUM1&2 repressive activity, requires functional CNOT deadenylase, and can operate autonomously when directed to an mRNA. The RD3 regions of PUM1&2 are likely in-

trinsically disordered (Goldstrohm et al. 2018) and directly bind to the carboxy-terminal NOT1-2-3 module of CNOT. We envision that the RBD of each PUM provides RNA-binding affinity and specificity, whereas the RD3 module binds to CNOT, thus rationalizing the modular architecture of PUM1&2. Together, these interactions effectively tether CNOT directly to target mRNAs where it can shorten the 3' poly(A) tail and initiate the degradation pathway.

Our results contribute to the growing body of evidence that the CNOT complex, and the NOT and CNOT9 modules in particular, serve as hubs for posttranscriptional regulation by sequence-specific RNA-binding regulatory factors (Goldstrohm and Wickens 2008; Temme et al. 2010) such as Roquin (Sgromo et al. 2017), TTP, microRNA induced silencing complex (Fabian et al. 2013; Jonas and Izaurralde 2015), and NANOS (Bhandari et al. 2014; Raisch et al. 2019). Interestingly, the *Drosophila* ortholog of NANOS synergizes with Pumilio to repress certain mRNAs (Weidmann et al. 2016; Arvola et al. 2017), hinting at general conservation of multivalent interactions between CNOT and specific RBPs.

As part of this study, we examined the effect of PUM1 missense mutations (Fig. 3A, T1035S, R1139W, or R1147W) that are associated with the neurodevelopmental disorders PADDAS and PRCA (Gennarino et al. 2018). Utilizing the altered specificity approach, we observed a minor but statistically significant decrease in their repression activities (Supplemental Fig. S6). While the R1147W and T1035S mutations were proposed to reduce PUM1 stability (Gennarino et al. 2018), it is possible the modest observed reduction in repression activity may be sufficient to trigger disease progression. The potential for these mutations to alter neuron-specific protein interactions or intracellular localization also warrants future study.

Functional specificity of deadenylases in PUM1&2-mediated repression

The CNOT complex contains two types of deadenylases enzymes, Pop2-type CNOT7&8 and Ccr4-type CNOT6&6L, that contribute to general mRNA deadenylation (Goldstrohm and Wickens 2008; Yi et al. 2018; Raisch et al. 2019). Surprisingly, we observed that depletion of CNOT7&8 alleviated repression whereas the depletion of CNOT6&6L had a minor effect, indicating an apparent functional specificity for Pop2-type deadenylases in PUM1&2-mediated repression. The fact that the two deadenylase types exhibit differences in catalytic properties in vitro (Raisch et al. 2019) and in vivo (Yi et al. 2018) is potentially relevant. Further, PABP negatively affects CNOT7&8 activity whereas it promotes deadenylation by CNOT6&6L (Webster et al. 2018; Yi et al. 2018). One hypothesis that should be tested in the future is that the functional deadenylase specificity of PUM1&2 may derive from their ability to antagonize PABP (Weidmann et al. 2014).

A role for decapping in PUM1&2-mediated repression

The observation that PUM1&2 can repress mRNAs that lack a poly(A) tail (e.g., MALAT1 or histone stem-loop [Van Etten et al. 2012]) suggests that there exists an additional facet to the repression mechanism. The fact that recruitment of the CNOT complex can elicit both deadenylation and deadenylation-independent translational repression is likely relevant (Cooke et al. 2010; Ozgur et al. 2015; Waghray et al. 2015; Kamenska et al. 2016; Räscher et al. 2020). Moreover, our data indicate that decapping contributes to repression by PUM1&2. In the 5'-to-3' mRNA decay pathway, decapping follows deadenylation (Garneau et al. 2007); although decapping mechanisms by RBPs have been shown to bypass deadenylation (Badis et al. 2004; Muhrad and Parker 2005). CNOT also directly binds to decapping factors (Jonas and Izaurralde 2013; Valkov et al. 2017) and the 5' exoribonuclease XRN1, which degrades decapped mRNAs (Chang et al. 2019). By exploiting the CNOT-mediated interactions in the decay network, PUM1&2 could consequently facilitate decapping of mRNA targets, which warrants future study.

Impact of PUM-CNOT mechanism on the transcriptome

PAC-Seq analysis shows that human PUM1&2 have a profound, wide impact on gene expression. We performed gene ontology (GO) analysis with the 890 genes that were up-regulated in response to PUM1&2 depletion. The most significantly enriched GO terms include positive regulation of RNA polymerase II transcription, MAPK signaling, regulation of cell migration, endocytosis, Wnt signaling, and post-embryonic development, as well as cancer terms (Supplemental Table S3). Many of these are direct targets of PUM1&2, based on the presence of PRE sites, evidence of binding by PUMs, and supported by comparative analyses (Bohn et al. 2018; Goldstrohm et al. 2018; Wolfe et al. 2020). Combining these PAC-Seq results from HCT116 cells with data from HEK293 cells (Bohn et al. 2018; Wolfe et al. 2020) increases the number of identified PUM1&2-repressed mRNAs to 1476. Further, 369 genes are mutually up-regulated by depletion of PUM1&2, CNOT1, and CNOT7&8, including known PUM targets (e.g., cell cycle factors CCNE2, CCNG2, CKS2, and cancer gene KRAS) (Bohn et al. 2018; Wolfe et al. 2020), which were enriched with similar gene ontologies as for PUM1&2 (Supplemental Table S3). Future research should explore the implications of PUM1&2 regulation of cancer genes and pathways, expanding upon existing links (Kedde et al. 2010; Miles et al. 2012; Naudin et al. 2017; Goldstrohm et al. 2018).

PUM1 and PUM2 carry 76% sequence identity, bind to the same PRE sequence, and both are broadly and coinci-

dentally expressed in tissues and cell lines (Spasov and Jurecic 2002; Goldstrohm et al. 2018). Our PAC-Seq data emphasize that they coregulate the majority of target mRNAs. There exists a small subset of targets, however, which is impacted by only one PUM, similar to the effects observed by others (Yamada et al. 2020). The determinants that make those mRNAs particularly responsive to one PUM, but not the other, remain to be identified and could include modulation by additional *cis*-acting sequence elements and/or *trans*-acting factors.

Conservation of repression mechanisms among PUF proteins

Accumulating evidence indicates that the repression mechanism of PUF proteins is conserved. In addition to the data reported here, evidence from worms (Suh et al. 2009), fruit flies (Kadyrova et al. 2007; Weidmann et al. 2014; Arvola et al. 2020), fission yeast (Webster et al. 2019), and budding yeast (Goldstrohm et al. 2006) support the central role of CNOT in PUF-mediated repression. The interaction of the highly conserved RBD of PUF proteins with CNOT appears to be universal (Goldstrohm et al. 2006; Hook et al. 2007; Kadyrova et al. 2007; Suh et al. 2009; Lee et al. 2010; Weidmann et al. 2014). In contrast, the amino-terminal repression domains that bind to CNOT, including RD3, are found in PUF proteins from organisms ranging from insects to vertebrates, but no homologous domains were detected in lower eukaryotes (Weidmann and Goldstrohm 2012; Goldstrohm et al. 2018). In *Drosophila*, the sole Pumilio protein has three distinct amino-terminal repression domains that can recruit CNOT to elicit repression (Weidmann and Goldstrohm 2012; Arvola et al. 2020), while an unrelated, unique region of the *S. pombe* PUF3 protein also binds CNOT (Webster et al. 2019). In addition to deadenylation, the involvement of the decapping factors in PUF-mediated repression is also conserved in humans (this study), *Drosophila* (Arvola et al. 2020), and *S. cerevisiae* (Olivas and Parker 2000; Goldstrohm et al. 2006; Blewett and Goldstrohm 2012). Collectively, this research highlights the deep evolutionary conservation of the PUF regulatory mechanisms that dynamically control transcriptomes.

In summary, our results reveal the molecular mechanism by which PUM1&2 recruit the mRNA decay machinery to regulate gene expression. This new fundamental knowledge is anticipated to promote understanding of the crucial regulatory roles of PUMs in development and differentiation in diverse contexts including embryos and germline, hematopoietic, and nervous systems.

MATERIALS AND METHODS

Plasmids and cloning

All oligonucleotides and plasmids used in this study are listed in Supplemental Tables S4, S5, respectively. The renilla luciferase

(Rluc) altered specificity reporter, Rluc 3xPRE UGG, was created in psiCheck1 (Promega) as previously described (Van Etten et al. 2012). Nano-luciferase (Nluc) reporters were cloned by replacing Rluc coding sequence in psiCheck1 with the NanolucP coding sequence (Promega) using XbaI and Sall sites to generate plasmid pNLP. The Nluc-based reporters were then generated by inserting three wild-type PREs (Nluc 3xPRE) or 3 mutant PREs (Nluc 3xPRE mt) into the XhoI and NotI sites of the 3'UTR using oligo cloning and inverse PCR (Van Etten et al. 2012; Bohn et al. 2018). The tethered function reporters Nluc 4xMS2 pA and Nluc 4xMS2 MALAT1, were similarly derived from pNLP as previously described (Abshire et al. 2018). The firefly luciferase (Fluc) plasmid, pGL4.13 (Promega), was used as a cotransfected control.

Expression plasmids for altered specificity (R6as) PUM1 and PUM2 full length and RBD constructs were previously described (Van Etten et al. 2012; Weidmann et al. 2014). PUM1 constructs with disease mutations (T1035S, R1139W, or R1147W [Gennarino et al. 2018]) were introduced into full length and RBD PUM1 R6as constructs using site-directed mutagenesis with oligos IE133/134, IE135/136, and IE137/138, respectively. The putative cap binding motifs (PUM1 W466G and PUM2 W350G) (Cao et al. 2010) were introduced in PUM1 and PUM2 full length R6as constructs using site-directed mutagenesis and oligos IE43/44 and IE120/121.

The tethered effector constructs PUM1 N (aa 1–827), PUM1 RD1 (aa 1–149), PUM1 RD2 (aa 309–459), PUM1 RD3 (aa 589–827), PUM1 RBD (aa 828–1175), PUM2 N (aa 1–704), PUM2 RD2 (aa 186–344), PUM2 RD3 (aa 471–704), PUM2 RBD (aa 705–1049) were Flexi cloned into mammalian expression vector pF5K (Promega) that contained the MS2 coat protein RNA-binding domain and a V5 epitope tag at the amino terminus. The tethered effectors pFN21A HT-MS2 and pFN21A HT-MS2 CNOT7 (Abshire et al. 2018) served as negative and positive controls, respectively, and were modified by inverse PCR with oligos IE177/178 and IE179/180, respectively, to include a V5 epitope tag.

The dominant negative CNOT7 (D40A, E42A) and CNOT8 (D40A, E42A) mutants were previously described (Piao et al. 2010; Van Etten et al. 2012). DCP2 (E148Q) dominant negative mutant (Chang et al. 2014) was generated by site directed mutagenesis using oligos IE128 and IE129 with template pcDNA3 myc DCP2 (provided by Dr. Jens Lykke Andersen, University of California). For coimmunoprecipitation assays, pF5A vector (Promega) served as a negative control and plasmid pFN21A CNOT8 with an amino-terminal V5 epitope tag was used as a positive control.

For the biochemical protein interaction assays, PUM constructs were created with amino-terminal Maltose Binding Protein (MBP) tag and a cleavage site for human rhinovirus (HRV3C) protease, along with a carboxy-terminal StrepII affinity tag. Human PUM constructs utilized in pull down assays included PUM1 RD1 (aa 1–149), PUM1 RD2 (aa 309–459), PUM1 RD3 (aa 589–827), PUM1 RBD (aa 828–1175), PUM2 RD2 (aa 186–344), PUM2 RD3 (aa 471–704), and PUM2 RBD (aa 705–1049). These inserts were cloned using Gibson assembly into the pNYC-pM vector that was linearized with NdeI (Gibson et al. 2009; Diebold et al. 2011; Arvola et al. 2020).

Cell culture and transfections

Human HCT116 cells (ATCC) were cultured at 37°C under 5% CO₂ in McCoy's 5A media (Thermo Fisher Scientific) with 1x pen-

icillin/streptomycin and 10% FBS (Invitrogen). Transfections were conducted using Fugene HD (Promega) according to the manufacturer's protocol with a ratio of 4 µL of Fugene HD to 1 µg of plasmid DNA. For 96-well reporter assays, 5000 cells were plated in white-walled 96 well plates. Twenty-four hours post seeding, the cells were transfected with 5 ng Fluc reporter plasmid and either 10 ng of Nluc or Rluc luciferase reporter plasmids (as indicated in the figures) and 85 ng of effector or control plasmid. For reporter assays involving overexpression of effectors and dominant negative mutants, cells were transfected with 5 ng Fluc reporter, 10 ng of Nluc reporter, 10 ng of effector and 37.5 ng of each of CNOT7 and CNOT8 mutant or 75 ng of the indicated negative control plasmid. For reporter assays involving overexpression of effectors and dominant negative DCP2 mutant, cells were transfected with 5 ng Fluc reporter, 10 ng of regulated Nluc reporter, 10 ng of effector and 75 ng of the DCP2 mutant plasmid or negative control plasmid, as indicated in the respective figures. For reporter assays with effector plasmid titrations, cells were transfected with 5 ng Fluc reporter, 10 ng of Nluc reporter, and the indicated amount of effector plasmid. Total mass of transfected plasmid was balanced in each sample by addition of pF5A vector to a maximum total of 85 ng. For reporter assays that were conducted in six-well format, specifically those that included RNA analysis, each well was seeded with 2×10^5 cells. After 24 h, cells were transfected using 0.5 µg FLuc and 1.25 µg of Nluc reporter along with 1.25 µg of the effector or control plasmid indicated in the figure. For coimmunoprecipitation assays, 7×10^6 HCT116 cells were seeded in a 100 mm dish and, after 24 h, were transfected with 17 µg of the indicated plasmid DNA using Fugene HD.

Reporter gene assays

The approach for luciferase-based PUM reporter gene assays was previously described (Van Etten et al. 2012, 2013; Bohn et al. 2018). In all reporter assays, an internal control Fluc reporter is cotransfected with the indicated Nluc reporter so as to normalize for potential variation in transfection efficiency. Three types of luciferase-based reporter genes were used in this study: (i) PRE-based reporters that measure repression by endogenous PUMs. (ii) Altered specificity PRE-based reporters that measure repression by transfected PUM effector proteins with programmed RNA binding specificity. (iii) Tethered function reporters that measure the regulatory activity of transfected MS2-fusion effector proteins.

To measure repression by endogenous PUM1&2, a Nluc reporter mRNA bearing three wild-type PREs in the 3'UTR (Nluc 3xPRE) was compared to a negative control reporter wherein the critical 5'-UGU sequence of each PRE was mutated to 5'-ACA (Nluc 3xPRE mt), as previously described (Van Etten et al. 2012; Bohn et al. 2018). This 5'-ACA mutation prevents binding by PUMs and eliminates repression activity (Van Etten et al. 2012; Bohn et al. 2018). Nluc and Fluc expression levels were measured using the Nano-glo Dual-luciferase reporter assay system (Promega) with a Glomax Discover luminometer (Promega).

To measure activity of wild-type and mutant PUM1 or PUM2 effectors without interference from endogenous PUMs, an altered specificity (as) assay was previously developed (Van Etten et al. 2012; Weidmann et al. 2014). PUM1&2 were programmed to

specifically bind a mutant PRE that has the 5'-UGU sequence changed to 5'-UGG (Van Etten et al. 2012). To do so, the RNA-recognition motif of the sixth repeat (R6) of each PUM RBD was changed to create PUM1 R6as and PUM2 R6as, which specifically bind and repress reporter mRNA bearing the PRE UGG (Rluc 3xPRE UGG) (Van Etten et al. 2012; Weidmann et al. 2014). This PRE UGG sequence is not recognized by the wild-type endogenous PUMs (Wang et al. 2002; Van Etten et al. 2012). Rluc and Fluc activity was measured using the Dual-Glo Assay system (Promega). Expression of Halotag (HT) (Promega) served as a negative control in these experiments.

A tethered function approach (Coller and Wickens 2002, 2007; Clement and Lykke-Andersen 2008) was used to measure the repressive activity of the amino terminus of PUM1 and PUM2, utilizing the Nluc 4xMS2 pA or Nluc 4xMS2 MALAT1 reporters that contained four stem-loop binding sites for the MS2 coat protein in their 3'UTR as previously described (Abshire et al. 2018). MS2 fusion protein effector constructs were expressed in conjunction with these reporters to measure their effect on gene expression. Nano-glo Dual-luciferase reporter assay was performed to measure the effects of each effector relative to the negative control MS2-Halotag (HT) fusion protein. As a positive control, experiments included the effector MS2-CNOT7 deadenylase, which causes robust repression and mRNA decay (Abshire et al. 2018).

Reporter assays were performed in 96-well format, unless noted otherwise. For reporter assays that included measurements of both reporter protein activity and mRNA level, a six-well format was used. Cells were trypsinized, counted, and reseeded with the same number of cells per well ($2-8 \times 10^4$) into white 96-well plate prior to measurements using the dual luciferase assays.

Reporter data analysis was performed as previously described (Van Etten et al. 2012, 2013; Bohn et al. 2018). For each sample, the relative response ratio (RRR) was calculated by normalizing Nluc, or Rluc, activity (measured in relative light units, RLU) to the corresponding Fluc value. These RRR values were then used to calculate fold change values between the indicated test conditions. For reporter assays measuring the activity of endogenous PUMs via PREs, fold change values were calculated from the RRR values for the PUM-regulated Nluc 3xPRE reporter relative to the unregulated mutant PRE reporter, Nluc 3xPRE mt. For RNAi experiments that tested the role of putative corepressors, the effect of each RNAi condition on PRE/PUM-mediated repression was measured within that same RNAi condition, as previously established (Arvola et al. 2020). In this manner, the specific effect of corepressor depletion on PRE/PUM activity is determined. The nontargeting control siRNA (NTC) served as negative control, whereas siRNAs for PUM1&2 served as a positive control. For altered specificity or tethered function assays, the fold change induced by an effector was calculated from RRR values relative to those for the negative control effector HT and MS2-HT, respectively.

All reporter assays were performed in three independent experiments with a total of nine replicates. The resulting data are reported as mean \log_2 fold change values along with standard error of the mean (SEM). Statistical significance of comparisons, indicated in the figures and legends, was calculated using Student's *t*-test (paired, two-tailed), and the resulting *P*-values, number and type of replicates, and data are reported in the figures and Supplemental Table S1.

RNA interference

RNAi mediated knockdown experiments were performed using Dharmacon On-Target Plus Smartpool siRNAs (Supplemental Table S4), which are optimized by the manufacturer to minimize potential off target effects. HCT116 cells were seeded at 2×10^5 per well of a six-well plate. After 24 h, the cells were transfected with 25 nM final concentration of the indicated siRNA using Dharmafect 4 (Dharmacon). A second transfection of siRNA was done after 24 h for the assays involving the following knockdown conditions; CNOT7 and CNOT8 (combined knockdown), CNOT6 and 6L (combined knockdown), CNOT10 and CNOT11. Twenty-four hours after the final siRNA treatment, cells were transfected with reporters as described above. Cells were harvested for assays 48 h after the reporter transfection. Efficiency of each RNAi treatment was confirmed by western blot and/or RT-qPCR (described below).

RNA purifications and cDNA preparation

For RNAi knockdown verification, RNA was purified from 2×10^6 HCT116 cells harvested 48 h following reporter transfection using the SimplyRNA cells kit and Maxwell RSC instrument (Promega) following the manufacturer's protocol. Twice the amount of DNase was added for the on-bead DNase treatment. Purified RNA was eluted in 40 μ L of nuclease-free water and then was quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific). For analysis of tethered function MS2 reporter mRNAs by RT-qPCR, RNA was purified from 2×10^6 HCT116 cells 48 h after reporter transfection. To ensure removal of potential DNA contamination, 3 μ g of purified RNA was incubated with 3 units of RQ1 DNase (Promega) at 37°C for 30 min. Next, the RNA was purified using an RNA Clean and Concentrator-25 spin-column (Zymo), eluted in 25 μ L of water, and again quantitated. Reverse transcription was then performed as previously described using GoScript reverse transcriptase (Promega) with random hexamer primers (Van Etten et al. 2012; Arvola et al. 2020).

Quantitative PCR

Quantitative PCR parameters are reported according to the MIQE guidelines in Supplemental File S1, including primer set sequences, amplicon size, and amplification efficiencies (Bustin et al. 2009). To confirm RNAi depletion of CNOT6, CNOT6L, CNOT7 and CNOT8, RT-qPCR was performed using GoTaq qPCR Master mix (Promega). Cycling conditions were as follows: (i) 95°C for 3 min, (ii) 95°C for 10 sec, (iii) 65°C for 30 sec (for CNOT7 and CNOT8), 60°C for 30 sec for (CNOT6 and 6L), or 65.5°C for 30 sec (for internal control 18S rRNA) and (iv) 72°C for 40 sec. Steps ii-iv were repeated a total of 40 cycles. Melt curves were then generated using 65°C-95°C as a range. For all primer sets, negative control reactions were performed in the absence of reverse transcriptase. Quantification cycles (Cq) were measured using the CFX Manager software (BioRad). Three experimental replicates were performed for each analysis. Fold change knockdown for each RNAi target gene was calculated relative to the NTC condition using the $\Delta\Delta$ Cq method as previously described (Pfaffl 2001). To measure RNA levels of the Nluc

4xMS2 BS pA reporter, the following cycling conditions were used: (i) 95°C for 3 min, (ii) 95°C for 10 sec, (iii) 63°C for 30 sec and (iv) 72°C for 40 sec. Steps ii–iv were repeated a total of 40 cycles. Melt curves were generated as previously stated. The non-coding, nonadenylated 18S rRNA was chosen as the internal control for these experiments because of the potential for deadenylase knockdown to affect the levels of potential control mRNAs.

Northern blotting

For northern blot experiments, cells were transfected in six-well format with the indicated reporter gene, Nluc 4xMS2 pA. Purified total RNA (3 µg) was separated by formaldehyde-agarose gel electrophoresis with 1x MOPS buffer and then transferred to Immobilon NY+ member (Millipore) as previously described (Arvola et al. 2020). The RNA integrity and loading of the RNA in each sample was assessed by staining with ethidium bromide. The blot was prehybridized for 1 h at 68°C in 10 mL of UltraHyb buffer (Invitrogen) and then was probed with an antisense RNA Nluc probe that was transcribed with α -³²P UTP (PerkinElmer) as described (Arvola et al. 2020). After overnight hybridization, the blots were washed twice in 25 mL of 2x SSC, 0.1% SDS and then twice in 0.1x SSC, 0.1% SDS at 68°C for 15 min. Blots were visualized by phosphorimaging with a Typhoon FLA phosphorimager (GE Life Sciences) and quantified using ImageQuant TL software (GE Life Sciences). The 18S rRNA was detected using a 5' ³²P-labeled antisense oligodeoxynucleotide probe (listed in Supplemental Table S4), prepared as previously described (Arvola et al. 2020). Prehybridized was done in 10 mL UltraHyb buffer for 1 h at 42°C and then the probe was incubated with the blot overnight. Blots were then washed twice with 25 mL 2xSSC containing 0.5% SDS for 30 min each wash at 42°C.

Immunoprecipitation assays

For coimmunoprecipitation analysis, 7×10^6 HCT116 cells were seeded in a 100 mm dish and, after 24 h, they were transfected with plasmids that expressed V5-tagged PUM1 RD3, PUM2 RD3, or CNOT8. Cells transfected with pF5A served as a negative control. After 48 h, cells were lysed by passing through a syringe four times in buffer A (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 0.5% Triton X100, and 1 mM EDTA) with 2x Complete protease inhibitor cocktail (Roche). The resulting cell lysate was cleared of cell debris by centrifugation at 4°C for 10 min at 20,000g. The supernatant was then centrifuged through a 0.45-micron filter at 4000g and the resulting cell extract was measured using the DC-Lowry assay (BioRad). One milligram of total cellular protein was then incubated with 30 µL bed volume of anti-V5 beads (Sigma), which were preequilibrated in buffer A, 4 µg of RNase A (Promega), and 40 units of RNase ONE (Promega) for 1.5 h at 4°C with end-over-end rotation. Beads were washed four times with buffer A for 5 min per wash with end-over-end rotation. Protein complexes were eluted in with 1x SDS-PAGE loading dye with heating at 42°C for 10 min. The eluted protein was collected and then analyzed by western blot. RNase digestion of cellular RNA was verified by purifying RNA from supernatant after immunoprecipitation using Reliaprep RNA purification kit (Promega) and then analyzing it by denaturing formaldehyde-

agarose gel electrophoresis followed by imaging of the ethidium bromide stained gel.

Western blotting

For western blots, HCT116 cells from one well of a 96-well plate were lysed in 50 µL radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with 2x Complete protease inhibitor cocktail (Roche) and lysed using a cell disruptor. Lysates were cleared by centrifugation at 20,000g for 10 min. Protein was quantified using Lowry DC Assay (BioRad) with a bovine serum albumin (BSA) standard curve. Equal mass of each cell extract (20 µg) was separated on a 4%–20% Mini-PROTEAN TGX gel (BioRad) and then transferred to Immobilon P membrane (Millipore) followed by Western blot with the primary antibodies indicated in the figures and detection by enhanced chemiluminescence (Pierce, Millipore). Antibodies are listed in Supplemental Table S5.

PAC-Seq library preparation and analysis

Isoform level changes in gene expression in response to RNAi of PUM1, PUM2, PUM1&2, or CNOT subunits were measured using Poly(A) Click Seq (PAC-Seq) as previously described (Routh et al. 2017; Elrod et al. 2019). First, 2×10^5 HCT116 cells were seeded in six-well format and then were transfected with the indicated siRNAs (25 nM) using Dharmafect 4 (6 µL per sample) as specified by the manufacturer (Dharmacon). Three biological replicate knockdowns were performed for each RNAi condition. After 48 h, the cells were harvested, and cell extracts prepared for western blot and RNA was extracted as described above. Knockdown of each RNAi target was verified by western blotting. Using the purified RNA, PAC-seq libraries were prepared as previously described (Routh et al. 2017). One microgram of total RNA was reverse transcribed with the partial P7 adapter (Illumina_4N_21T) and dNTPs with the addition of spiked-in azido-nucleotides (AzVTPs) at 5:1. The p5 adapter (IDT) was Click-ligated to the 5' end of the cDNA with CuAAC. The cDNA was then amplified for 16 cycles using the Universal primer and 3' indexing primer, followed by purification on a 2% agarose gel with extraction of the 200–300 bp amplicon. Barcoded libraries were then pooled and sequenced with single-end, 150 bp reads on a Nextseq 550 (Illumina).

PAC-seq data was analyzed with the DPAC pipeline v1.10 (Routh 2019) using the exon centric approach with the –P –M –C –A –B and –D options. Alignments were to the hg38 genome using the Gencode v32 annotation. Results were filtered such that genes or exons required a minimum 5 mean reads in each sample, a 1.3-fold change, and an adjusted *P*-value <0.05 to be scored as significantly differentially expressed. Genes with more than one poly(A)-site (PAS) additionally required a percent distal PAS usage change of 20 percent to be considered a change in 3'UTR isoform. The resulting differential expression analysis and statistics are reported in Supplemental Table S2. Tests for statistical significance of overlapping gene expression sets were performed using the R package SuperExactTest v1.0.7.1 (Wang et al. 2015) which uses a hypergeometric test for multiset overlap. The gene lists and statistics for the comparative analyses are

reported in Supplemental Table S3. Gene ontology analysis was performed using DAVID v6.8 (Dennis et al. 2003) and top enriched GO terms are listed in Supplemental Table S3.

In vitro pull-down assays

In vitro pull-down assays were performed to detect protein interactions between domains of PUM1 and PUM2 and the reconstituted, purified CNOT complex, as previously described (Arvola et al. 2020). StrepII- and MBP-tagged human PUM1 and PUM2 RD and RBD constructs were expressed in *E. coli* BL21 (DE3) Star cells (Thermo Fisher Scientific). Cells were grown in LB overnight at 37°C. Cells were lysed (8 mM Na₂HPO₄, 137 mM NaCl, 2 mM KH₂PO₄, 2.7 mM KCl, 0.3% [v/v] Tween-20, pH 7.4) and cleared. Lysate was incubated for 1 h with 30 µL (50% slurry) of StrepTactin sepharose resin (IBA). Beads were then washed three times with lysis buffer and once with binding buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl). Fifty micrograms of purified human CNOT complex was added to beads and incubated for 1 h. For the intact CNOT complex, the protein components were as follows: CNOT1 (amino acids 1–2376), CNOT2 (aa 1–540), CNOT3 (aa 1–753), CNOT10 (aa 25–707), CNOT11 (aa 257–498), CNOT7 (aa 1–285), CNOT6 (aa 1–558), CNOT9 (aa 1–299) (Raisch et al. 2019). For the pull-down analysis of CNOT modules, the following purified components were used: catalytic module contained NOT1 (aa 1093–1317), CNOT6 (aa 1–563), CNOT7 (aa 1–285); the NOT10/11 module contained CNOT1 (aa 1–682), CNOT10 (aa 25–707), CNOT11 (aa 257–498); the CNOT9 module contained NOT1 (aa 1351–1588), CNOT9 (aa 19–285); NOT module contained CNOT1 (aa 1833–2361), CNOT2 (aa 344–540), and CNOT3 (aa 607–753). Post incubation beads were washed three times with the binding buffer and then bound proteins were eluted with the binding buffer containing 2.5 mM D-desthiobiotin. Proteins were analyzed by Coomassie blue stained SDS-PAGE.

DATA DEPOSITION

All unique/stable reagents generated in this study are available from the Lead Contact without restriction. The (data sets/code) generated during this study are available at the Gene Expression Omnibus (GSE159510).

SUPPLEMENTAL MATERIAL

Supplemental material is available for this article.

COMPETING INTEREST STATEMENT

E.J.W. is listed as a coinventor for a pending patent application for PAC-Seq.

ACKNOWLEDGMENTS

The authors wish to thank members of the Goldstrohm, Valkov, and Wagner laboratories for helpful suggestions and feedback. This research was funded by grants from the National Institute of General Medical Sciences, National Institutes of Health

(R01GM105707 to A.C.G.) and American Cancer Society Research Scholar Grant (RSG-13–080-01-RMC to A.C.G.); Max Planck Society (to E.V.); NIH, National Institute of General Medical Sciences (R01-GM134539 to E.J.W.); NIH, National Cancer Institute (R03-CA223893-01 to P.J.). Publication costs were paid by University of Minnesota institutional funds.

Author contributions: I.E.: lead author, conceptualization, methodology, investigation, formal analysis, visualization, writing—original draft, review, editing; N.E.: methodology, formal analysis, visualization, editing; J.B.: resources, investigation, editing; C.C.: resources, investigation; Y.L.: resources, investigation; P.J.: investigation; A.L.: investigation; E.V.: conceptualization, experimental design, visualization, writing—review, editing, funding acquisition; E.J.W.: conceptualization, methodology, funding acquisition, editing draft; A.C.G.: conceptualization, experimental design, analysis, visualization, writing—original draft, review, editing, project administration, funding acquisition.

Received November 17, 2020; accepted December 28, 2020.

REFERENCES

- Abshire ET, Chasseur J, Bohn JA, Del Rizzo PA, Freddolino PL, Goldstrohm AC, Trievel RC. 2018. The structure of human nocturnin reveals a conserved ribonuclease domain that represses target transcript translation and abundance in cells. *Nucleic Acids Res* **46**: 6257–6270. doi:10.1093/nar/gky412
- Arvola RM, Weidmann CA, Tanaka Hall TM, Goldstrohm AC. 2017. Combinatorial control of messenger RNAs by Pumilio, nanos and brain tumor proteins. *RNA Biol* **14**: 1445–1456. doi:10.1080/15476286.2017.1306168
- Arvola RM, Chang C-T, Buytendorp JP, Levdansky Y, Valkov E, Freddolino PL, Goldstrohm AC. 2020. Unique repression domains of Pumilio utilize deadenylation and decapping factors to accelerate destruction of target mRNAs. *Nucleic Acids Res* **48**: 1843–1871. doi:10.1093/nar/gkz1187
- Badis G, Saveanu C, Fromont-Racine M, Jacquier A. 2004. Targeted mRNA degradation by deadenylation-independent decapping. *Mol Cell* **15**: 5–15. doi:10.1016/j.molcel.2004.06.028
- Behm-Ansmant I, Rehwinkel J, Doerks T, Stark A, Bork P, Izaurralde E. 2006. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. *Genes Dev* **20**: 1885–1898. doi:10.1101/gad.1424106
- Bhandari D, Raisch T, Weichenrieder O, Jonas S, Izaurralde E. 2014. Structural basis for the nanos-mediated recruitment of the CCR4-NOT complex and translational repression. *Genes Dev* **28**: 888–901. doi:10.1101/gad.237289.113
- Blewett NH, Goldstrohm AC. 2012. A eukaryotic translation initiation factor 4E-binding protein promotes mRNA decapping and is required for PUF repression. *Mol Cell Biol* **32**: 4181–4194. doi:10.1128/MCB.00483-12
- Bohn JA, Van Etten JL, Schagat TL, Bowman BM, McEachin RC, Freddolino PL, Goldstrohm AC. 2018. Identification of diverse target RNAs that are functionally regulated by human pumilio proteins. *Nucleic Acids Res* **46**: 362–386. doi:10.1093/nar/gkx1120
- Boland A, Chen Y, Raisch T, Jonas S, Kuzuoğlu-Öztürk D, Wohlbold L, Weichenrieder O, Izaurralde E. 2013. Structure and assembly of the NOT module of the human CCR4-NOT complex. *Nat Struct Mol Biol* **20**: 1289–1297. doi:10.1038/nsmb.2681
- Brown JA, Bulkley D, Wang J, Valenstein ML, Yario TA, Steitz TA, Steitz JA. 2014. Structural insights into the stabilization of MALAT1 noncoding RNA by a bipartite triple helix. *Nat Struct Mol Biol* **21**: 633–640. doi:10.1038/nsmb.2844

- Bustin SA, Benes V, Garson JA, Hellems J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, et al. 2009. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem* **55**: 611–622. doi:10.1373/clinchem.2008.112797
- Cao Q, Padmanabhan K, Richter JD. 2010. Pumilio 2 controls translation by competing with eIF4E for 7-methyl guanosine cap recognition. *RNA* **16**: 221–227. doi:10.1261/ma.1884610
- Chang C-T, Bercovich N, Loh B, Jonas S, Izaurralde E. 2014. The activation of the decapping enzyme DCP2 by DCP1 occurs on the EDC4 scaffold and involves a conserved loop in DCP1. *Nucleic Acids Res* **42**: 5217–5233. doi:10.1093/nar/gku129
- Chang C-T, Muthukumar S, Weber R, Levdansky Y, Chen Y, Bhandari D, Igreja C, Wohlbold L, Valkov E, Izaurralde E. 2019. A low-complexity region in human XRN1 directly recruits deadenylation and decapping factors in 5'–3' messenger RNA decay. *Nucleic Acids Res* **47**: 9282–9295. doi:10.1093/nar/gkz633
- Chen Y, Boland A, Kuzuoğlu-Öztürk D, Bawankar P, Loh B, Chang C-T, Weichenrieder O, Izaurralde E. 2014. A DDX6-CNOT1 complex and W-binding pockets in CNOT9 reveal direct links between miRNA target recognition and silencing. *Mol Cell* **54**: 737–750. doi:10.1016/j.molcel.2014.03.034
- Cheong CG, Tanaka Hall TM. 2006. Engineering RNA sequence specificity of pumilio repeats. *Proc Natl Acad Sci* **103**: 13635–13639. doi:10.1073/pnas.0606294103
- Clement SL, Lykke-Andersen J. 2008. A tethering approach to study proteins that activate mRNA turnover in human cells. In *Post-transcriptional gene regulation* (ed. Wilusz J), pp. 121–133. Humana Press, Totowa, NJ.
- Coller J, Wickens M. 2002. Tethered function assays using 3' untranslated regions. *Methods* **26**: 142–150. doi:10.1016/S1046-2023(02)00016-6
- Coller J, Wickens M. 2007. Chapter fourteen: tethered function assays: an adaptable approach to study RNA regulatory proteins. *Methods Enzymol* **429**: 299–321. doi:10.1016/S0076-6879(07)29014-7
- Cooke A, Prigge A, Wickens M. 2010. Translational repression by deadenylases. *J Biol Chem* **285**: 28506–28513. doi:10.1074/jbc.M110.150763
- Covarrubias S, Gaglia MM, Renuka Kumar G, Wong W, Jackson AO, Glausinger BA. 2011. Coordinated destruction of cellular messages in translation complexes by the gammaherpesvirus host shutoff factor and the mammalian exonuclease Xrn1. *PLoS Pathog* **7**: e1002339. doi:10.1371/journal.ppat.1002339
- Dennis G, Jr BT, Sherman DA, Hosack JY, Gao W, Clifford Lane H, Lempicki RA. 2003. DAVID: database for annotation, visualization, and integrated discovery. *Genome Biol* **4**: P3. doi:10.1186/gb-2003-4-5-p3
- Diebold M-L, Fribourg S, Koch M, Metzger T, Romier C. 2011. Deciphering correct strategies for multiprotein complex assembly by co-expression: application to complexes as large as the histone octamer. *J Struct Biol* **175**: 178–188. doi:10.1016/j.jsb.2011.02.001
- Elrod ND, Jaworski EA, Ji P, Wagner EJ, Routh A. 2019. Development of poly(A)-ClickSeq as a tool enabling simultaneous genome-wide poly(A)-site identification and differential expression analysis. *Methods* **155**: 20–29. doi:10.1016/j.ymeth.2019.01.002
- Erickson SL, Corpuz EO, Maloy JP, Fillman C, Webb K, Bennett EJ, Lykke-Andersen J. 2015. Competition between decapping complex formation and ubiquitin-mediated proteasomal degradation controls human Dcp2 decapping activity. *Mol Cell Biol* **35**: 2144–2153. doi:10.1128/MCB.01517-14
- Fabian MR, Frank F, Rouya C, Siddiqui N, Lai WS, Karetnikov A, Blakeshear PJ, Nagar B, Sonenberg N. 2013. Structural basis for the recruitment of the human CCR4-NOT deadenylase complex by tristetraprolin. *Nat Struct Mol Biol* **20**: 735–739. doi:10.1038/nsmb.2572
- Follwaczny P, Schieweck R, Riedemann T, Demleitner A, Straub T, Klemm AH, Bilban M, Sutor B, Popper B, Kiebler MA. 2017. Pumilio2-deficient mice show a predisposition for epilepsy. *Dis Model Mech* **10**: 1333–1342. doi:10.1242/dmm.029678
- Galgano A, Forrer M, Jaskiewicz L, Kanitz A, Zavolan M, Gerber AP. 2008. Comparative analysis of mRNA targets for human PUF-family proteins suggests extensive interaction with the miRNA regulatory system. *PLoS One* **3**: e3164. doi:10.1371/journal.pone.0003164
- Garneau NL, Wilusz J, Wilusz CJ. 2007. The highways and byways of mRNA decay. *Nat Rev Mol Cell Biol* **8**: 113–126. doi:10.1038/nrm2104
- Gehring NH, Wahle E, Fischer U. 2017. Deciphering the mRNP code: RNA-bound determinants of post-transcriptional gene regulation. *Trends Biochem Sci* **42**: 369–382. doi:10.1016/j.tibs.2017.02.004
- Gennarino VA, Singh RK, White JJ, De Maio A, Han K, Kim J-Y, Jafar-Nejad P, di Ronza A, Kang H, Sayegh LS, et al. 2015. Pumilio1 haploinsufficiency leads to SCA1-like neurodegeneration by increasing wild-type ataxin1 levels. *Cell* **160**: 1087–1098. doi:10.1016/j.cell.2015.02.012
- Gennarino VA, Palmer EE, McDonell LM, Wang L, Adamski CJ, Koire A, See L, Chen CA, Schaaf CP, Rosenfeld JA, et al. 2018. A mild PUM1 mutation is associated with adult-onset ataxia, whereas haploinsufficiency causes developmental delay and seizures. *Cell* **172**: 924–936.e11. doi:10.1016/j.cell.2018.02.006
- Gerstberger S, Hafner M, Tuschl T. 2014. A census of human RNA-binding proteins. *Nat Rev Genet* **15**: 829–845. doi:10.1038/nrg3813
- Gibson DG, Young L, Chuang R-Y, Craig Venter J, Hutchison CA III, Smith HO. 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nat Methods* **6**: 343–345. doi:10.1038/nmeth.1318
- Goldstrohm AC, Wickens M. 2008. Multifunctional deadenylase complexes diversify mRNA control. *Nat Rev Mol Cell Biol* **9**: 337–344. doi:10.1038/nrm2370
- Goldstrohm AC, Hook BA, Seay DJ, Wickens M. 2006. PUF proteins bind Pop2p to regulate messenger RNAs. *Nat Struct Mol Biol* **13**: 533–539. doi:10.1038/nsmb1100
- Goldstrohm AC, Tanaka Hall TM, McKenney KM. 2018. Post-transcriptional regulatory functions of mammalian pumilio proteins. *Trends Genet* **34**: 972–990. doi:10.1016/j.tig.2018.09.006
- Hafner M, Landthaler M, Burger L, Khorshid M, Munschauer J, Berninger P, Rothballer A, Ascano M, Jungkamp A-C, Hunschauer M, et al. 2010. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. *Cell* **141**: 129–141. doi:10.1016/j.cell.2010.03.009
- Hook BA, Goldstrohm AC, Seay DJ, Wickens M. 2007. Two yeast PUF proteins negatively regulate a single mRNA. *J Biol Chem* **282**: 15430–15438. doi:10.1074/jbc.M611253200
- Jarmoskaite I, Denny SK, Vaidyanathan PP, Becker WR, Andreasson JOL, Layton CJ, Kappel K, Shivashankar V, Sreenivasan R, Das R, et al. 2019. A quantitative and predictive model for RNA binding by human pumilio proteins. *Mol Cell* **74**: 966–981.e18. doi:10.1016/j.molcel.2019.04.012
- Jonas S, Izaurralde E. 2013. The role of disordered protein regions in the assembly of decapping complexes and RNP granules. *Genes Dev* **27**: 2628–2641. doi:10.1101/gad.227843.113
- Jonas S, Izaurralde E. 2015. Towards a molecular understanding of microRNA-mediated gene silencing. *Nat Rev Genet* **16**: 421–433. doi:10.1038/nrg3965
- Kadyrova LY, Habara Y, Lee TH, Wharton RP. 2007. Translational control of maternal cyclin B mRNA by nanos in the *Drosophila* germline. *Development* **134**: 1519–1527. doi:10.1242/dev.002212

- Kamenska A, Simpson C, Vindry C, Broomhead H, Bénard M, Ernoult-Lange M, Lee BP, Harries LW, Weil D, Standart N. 2016. The DDX6-4E-T interaction mediates translational repression and P-body assembly. *Nucleic Acids Res* **44**: 6318–6334. doi:10.1093/nar/gkw565
- Kedde M, van Kouwenhove M, Zwart W, Oude Vrielink JAF, Elkon R, Agami R. 2010. A Pumilio-induced RNA structure switch in p27-3' UTR controls miR-221 and miR-222 accessibility. *Nat Cell Biol* **12**: 1014–1020. doi:10.1038/ncb2105
- Lau N-C, Kolkman A, van Schaik FMA, Mulder KW, Pim Pijnappel WWM, Heck AJR, Marc Timmers HT. 2009. Human Ccr4-Not complexes contain variable deadenylase subunits. *Biochem J* **422**: 443–453. doi:10.1042/BJ20090500
- Lee D, Ohn T, Chiang Y-C, Quigley G, Yao G, Liu Y, Denis CL. 2010. PUF3 acceleration of deadenylation in vivo can operate independently of CCR4 activity, possibly involving effects on the PAB1-mRNP structure. *J Mol Biol* **399**: 562–575. doi:10.1016/j.jmb.2010.04.034
- Lee S, Kopp F, Chang T-C, Sataluri A, Chen B, Sivakumar S, Yu H, Xie Y, Mendell JT. 2016. Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins. *Cell* **164**: 69–80. doi:10.1016/j.cell.2015.12.017
- Lin K, Zhang S, Shi Q, Zhu M, Gao L, Xia W, Geng B, Zheng Z, Xu EY. 2018. Essential requirement of mammalian pumilio family in embryonic development. *Mol Biol Cell* **29**: 2922–2932. doi:10.1091/mbc.E18-06-0369
- Lin K, Qiang W, Zhu M, Ding Y, Shi Q, Chen X, Zsiros E, Wang K, Yang X, Kurita T, et al. 2019. Mammalian Pum1 and Pum2 control body size via translational regulation of the cell cycle inhibitor Cdkn1b. *Cell Rep* **26**: 2434–2450.e6. doi:10.1016/j.celrep.2019.01.111
- Loh B, Jonas S, Izaurralde E. 2013. The SMG5–SMG7 heterodimer directly recruits the CCR4–NOT deadenylase complex to mRNAs containing nonsense codons via interaction with POP2. *Genes Dev* **27**: 2125–2138. doi:10.1101/gad.226951.113
- Lu G, Tanaka Hall TM. 2011. Alternate modes of cognate RNA recognition by human PUMILIO proteins. *Structure* **19**: 361–367. doi:10.1016/j.str.2010.12.019
- Lu G, Dolgner SJ, Tanaka Hall TM. 2009. Understanding and engineering RNA sequence specificity of PUF proteins. *Curr Opin Struct Biol* **19**: 110–115. doi:10.1016/j.sbi.2008.12.009
- Mathys H, Basquin J, Ozgur S, Czarnocki-Cieciura M, Bonneau F, Aartse A, Dziembowski A, Nowotny N, Conti E, Filipowicz W. 2014. Structural and biochemical insights to the role of the CCR4–NOT complex and DDX6 ATPase in microRNA repression. *Mol Cell* **54**: 751–765. doi:10.1016/j.molcel.2014.03.036
- Miles WO, Tschöp K, Herr A, Ji J-Y, Dyson NJ. 2012. Pumilio facilitates miRNA regulation of the E2F3 oncogene. *Genes Dev* **26**: 356–368. doi:10.1101/gad.182568.111
- Mishima Y, Tomari Y. 2016. Codon usage and 3' UTR length determine maternal mRNA stability in zebrafish. *Mol Cell* **61**: 874–885. doi:10.1016/j.molcel.2016.02.027
- Morris AR, Mukherjee N, Keene JD. 2008. Ribonomic analysis of human Pum1 reveals cis-trans conservation across species despite evolution of diverse mRNA target sets. *Mol Cell Biol* **28**: 4093–4103. doi:10.1128/MCB.00155-08
- Muhrad D, Parker R. 2005. The yeast EDC1 mRNA undergoes deadenylation-independent decapping stimulated by Not2p, Not4p, and Not5p. *EMBO J* **24**: 1033–1045. doi:10.1038/sj.emboj.7600560
- Naudin C, Hattabi A, Michelet F, Miri-Nezhad A, Benyoucef A, Pflumio F, Guillonneau F, Fichelson S, Vigon I, Dusanter-Fourt I, et al. 2017. PUMILIO/FOXP1 signaling drives expansion of hematopoietic stem/progenitor and leukemia cells. *Blood* **129**: 2493–2506. doi:10.1182/blood-2016-10-747436
- Olivas W, Parker R. 2000. The Puf3 protein is a transcript-specific regulator of mRNA degradation in yeast. *EMBO J* **19**: 6602–6611. doi:10.1093/emboj/19.23.6602
- Ozgur S, Basquin J, Kamenska A, Filipowicz W, Standart N, Conti E. 2015. Structure of a human 4E-T/DDX6/CNOT1 complex reveals the different interplay of DDX6-binding proteins with the CCR4–NOT complex. *Cell Rep* **13**: 703–711. doi:10.1016/j.celrep.2015.09.033
- Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* **29**: e45. doi:10.1093/nar/29.9.e45
- Piao X, Zhang X, Wu L, Belasco JG. 2010. CCR4–NOT deadenylates mRNA associated with RNA-induced silencing complexes in human cells. *Mol Cell Biol* **30**: 1486–1494. doi:10.1128/MCB.01481-09
- Raisch T, Sandmeir F, Weichenrieder O, Valkov E, Izaurralde E. 2018. Structural and biochemical analysis of a NOT1 MIF4G-like domain of the CCR4–NOT complex. *J Struct Biol* **204**: 388–395. doi:10.1016/j.jsb.2018.10.009
- Raisch T, Chang C-T, Levdansky Y, Muthukumar S, Raunser S, Valkov E. 2019. Reconstitution of recombinant human CCR4–NOT reveals molecular insights into regulated deadenylation. *Nat Commun* **10**: 3173. doi:10.1038/s41467-019-11094-z
- Räsch F, Weber R, Izaurralde E, Igreja C. 2020. 4E-T-bound mRNAs are stored in a silenced and deadenylated form. *Genes Dev* **34**: 847–860. doi:10.1101/gad.336073.119
- Routh A. 2019. DPAC: a tool for differential poly(A)-cluster usage from poly(A)-targeted RNAseq data. *G3 (Bethesda)* **9**: 1825–1830.
- Routh A, Ji P, Jaworski E, Xia Z, Li W, Wagner EJ. 2017. Poly(A)-ClickSeq: click-chemistry for next-generation 3'-end sequencing without RNA enrichment or fragmentation. *Nucleic Acids Res* **45**: e112. doi:10.1093/nar/gkx286
- Sgromo A, Raisch T, Bawankar P, Bhandari D, Chen Y, Kuzuoğlu-Öztürk D, Weichenrieder O, Izaurralde E. 2017. A CAF40-binding motif facilitates recruitment of the CCR4–NOT complex to mRNAs targeted by Drosophila roquin. *Nat Commun* **8**: 14307. doi:10.1038/ncomms14307
- Spasov DS, Jurecic R. 2002. Cloning and comparative sequence analysis of PUM1 and PUM2 genes, human members of the pumilio family of RNA-binding proteins. *Gene* **299**: 195–204. doi:10.1016/S0378-1119(02)01060-0
- Suh N, Crittenden SL, Goldstrohm A, Hook B, Thompson B, Wickens M, Kimble J. 2009. FBF and its dual control of Gld-1 expression in the *Caenorhabditis elegans* germline. *Genetics* **181**: 1249–1260. doi:10.1534/genetics.108.099440
- Temme C, Zhang L, Kremmer E, Ihling C, Chartier A, Sinz A, Simonelig M, Wahle E. 2010. Subunits of the Drosophila CCR4–NOT complex and their roles in mRNA deadenylation. *RNA* **16**: 1356–1370. doi:10.1261/rna.2145110
- Uyhazi KE, Yang Y, Liu N, Qi H, Huang XA, Mak W, Weatherbee SD, de Prisco N, Gennarino VA, Song X, et al. 2020. Pumilio proteins utilize distinct regulatory mechanisms to achieve complementary functions required for pluripotency and embryogenesis. *Proc Natl Acad Sci* **117**: 7851–7862. doi:10.1073/pnas.1916471117
- Valkov E, Jonas S, Weichenrieder O. 2017. Mille viae in eukaryotic mRNA decapping. *Curr Opin Struct Biol* **47**: 40–51. doi:10.1016/j.sbi.2017.05.009
- Van Etten J, Schagat TL, Hrit J, Weidmann CA, Brumbaugh J, Coon JJ, Goldstrohm AC. 2012. Human pumilio proteins recruit multiple deadenylases to efficiently repress messenger RNAs. *J Biol Chem* **287**: 36370–36383. doi:10.1074/jbc.M112.373522
- Van Etten J, Schagat TL, Goldstrohm AC. 2013. A guide to design and optimization of reporter assays for 3' untranslated region mediated regulation of mammalian messenger RNAs. *Methods* **63**: 110–118. doi:10.1016/j.ymeth.2013.04.020

- Waghray S, Williams C, Coon JJ, Wickens M. 2015. Xenopus CAF1 requires NOT1-mediated interaction with 4E-T to repress translation in vivo. *RNA* **21**: 1335–1345. doi:10.1261/rna.051565.115
- Wang X, McLachlan J, Zamore PD, Tanaka Hall TM. 2002. Modular recognition of RNA by a human pumilio-homology domain. *Cell* **110**: 501–512. doi:10.1016/S0092-8674(02)00873-5
- Wang M, Zhao Y, Zhang B. 2015. Efficient test and visualization of multi-set intersections. *Sci Rep* **5**: 16923. doi:10.1038/srep16923
- Webster MW, Chen Y-H, Stowell JAW, Alhusaini N, Sweet T, Graveley BR, Collier J, Passmore LA. 2018. mRNA deadenylation is coupled to translation rates by the differential activities of Ccr4-Not nucleases. *Mol Cell* **70**: 1089–1100.e8. doi:10.1016/j.molcel.2018.05.033
- Webster MW, Stowell JA, Passmore LA. 2019. RNA-binding proteins distinguish between similar sequence motifs to promote targeted deadenylation by Ccr4-Not. *Elife* **8**: e40670. doi:10.7554/eLife.40670
- Weidmann CA, Goldstrohm AC. 2012. Drosophila pumilio protein contains multiple autonomous repression domains that regulate mRNAs independently of nanos and brain tumor. *Mol Cell Biol* **32**: 527–540. doi:10.1128/MCB.06052-11
- Weidmann CA, Raynard NA, Blewett NH, Van Etten J, Goldstrohm AC. 2014. The RNA binding domain of pumilio antagonizes poly-adenosine binding protein and accelerates deadenylation. *RNA* **20**: 1298–1319. doi:10.1261/rna.046029.114
- Weidmann CA, Qiu C, Arvola RM, Lou T-F, Killingsworth J, Campbell ZT, Tanaka Hall TM, Goldstrohm AC. 2016. Drosophila nanos acts as a molecular clamp that modulates the RNA-binding and repression activities of pumilio. *Elife* **5**: e17096. doi:10.7554/eLife.17096
- Wickens M, Bernstein DS, Kimble J, Parker R. 2002. A PUF family portrait: 3'UTR regulation as a way of life. *Trends Genet* **18**: 150–157. doi:10.1016/S0168-9525(01)02616-6
- Wilusz JE. 2016. Long noncoding RNAs: re-writing dogmas of RNA processing and stability. *Biochim Biophys Acta* **1859**: 128–138. doi:10.1016/j.bbagr.2015.06.003
- Wilusz JE, JnBaptiste CK, Lu LY, Kuhn C-D, Joshua-Tor L, Sharp PA. 2012. A triple helix stabilizes the 3' ends of long noncoding RNAs that lack poly(A) tails. *Genes Dev* **26**: 2392–2407. doi:10.1101/gad.204438.112
- Wolfe MB, Schagat TL, Paulsen MT, Magnuson B, Ljungman M, Park D, Zhang C, Campbell ZT, Goldstrohm AC, Freddolino PL. 2020. Principles of mRNA control by human PUM proteins elucidated from multi-modal experiments and integrative data analysis. *RNA* **26**: 1680–1703. doi:10.1261/rna.077362.120
- Yamada T, Imamachi N, Imamura K, Taniue K, Kawamura T, Suzuki Y, Nagahama M, Akimitsu N. 2020. Systematic analysis of targets of pumilio-mediated mRNA decay reveals that PUM1 repression by DNA damage activates translesion synthesis. *Cell Rep* **31**: 107542. doi:10.1016/j.celrep.2020.107542
- Yamashita A, Chang T-C, Yamashita Y, Zhu W, Zhong Z, Chen C-YA, Shyu A-B. 2005. Concerted action of poly(A) nucleases and decapping enzyme in mammalian mRNA turnover. *Nat Struct Mol Biol* **12**: 1054–1063. doi:10.1038/nsmb1016
- Yi H, Park J, Ha M, Lim J, Chang H, Narry Kim V. 2018. PABP cooperates with the CCR4-NOT complex to promote mRNA deadenylation and block precocious decay. *Mol Cell* **70**: 1081–1088.e5. doi:10.1016/j.molcel.2018.05.009
- Zamore PD, Williamson JR, Lehmann R. 1997. The pumilio protein binds RNA through a conserved domain that defines a new class of RNA-binding proteins. *RNA* **3**: 1421–1433.
- Zhang M, Chen D, Xia J, Han W, Cui X, Neuenkirchen N, Hermes G, Sestan N, Lin H. 2017. Post-transcriptional regulation of mouse neurogenesis by pumilio proteins. *Genes Dev* **31**: 1354–1369. doi:10.1101/gad.298752.117